Investigating the effect of the pro-inflammatory messenger interleukin-5 on antibody-secreting immune cells in the nose
Not Applicable
- Conditions
- asal polypsEar, Nose and Throat
- Registration Number
- ISRCTN16169610
- Lead Sponsor
- Queen Mary University of London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
1. Patients undergoing resection of nasal tissue for clinical indications (e.g. polypectomy, turbinectomy, septoplasty, tonsilectomy)
2. Able to give consent
3. Aged 18 years and over
The researchers will specifically recruit the following subgroups:
1. Patients undergoing nasal polyp resections, who are not on biologics
2. Patients undergoing nasal polyp resections, who are on anti-IL-5 biologics
3. Patients undergoing nasal operations other than polyp resection
Exclusion Criteria
1. Inability to give consent
2. Previous rituximab treatment (ever)
3. Chemotherapy with preceding 6 months
4. Cystic fibrosis
5. Pregnancy or breastfeeding
6. Known current COVID infection/TB infection
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The B cell receptor (BCR) (antibody immunoglobulin) repertoire of tissue-resident airway B-cells, in particular the relative expression of different immunoglobulin classes and subclasses. Measured using single-cell and bulk RNA sequencing at baseline.
- Secondary Outcome Measures
Name Time Method BCR repertoires for convergent clonotypes evident in blood (from IDEA project) and other available BCR libraries, to assess for potential pathological clonotypes in eosinophilic airway inflammation. Measured using single-cell and bulk RNA sequencing at baseline.